BIOHAVEN LTD (BHVN)
VGG1110E1079 - Common Stock
Shhh! 3 Secret Biotech Stocks Flying Below Wall Street’s Radar
These biotech stocks seem to be rich with intriguing growth plays going for very reasonable multiples this May.
3 Biotech Stocks to Buy on the Dip: April 2024
With medical innovation being a resilient space, investors can have confidence with these biotech stocks to buy on the dip.
Bargain Hunters Take Note: Insider Cluster-Buying At BHVN
Tuesday 4/23 Insider Buying Report: BHVN, LIND
Biohaven Announces Closing of Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares
/PRNewswire/ -- Biohaven Ltd. (NYSE: BHVN), a biopharmaceutical company focused on the discovery, development, and commercialization of life-changing...
Investors Snag BHVN 8.3% Lower Than Its Secondary Stock Offering
Oversold Conditions For Biohaven (BHVN)
Biohaven Announces Pricing of $230 Million Public Offering of Common Shares
/PRNewswire/ -- Biohaven Ltd. (NYSE: BHVN), a biopharmaceutical company focused on the discovery, development, and commercialization of life-changing...
Biohaven Announces Proposed Public Offering of Common Shares
/PRNewswire/ -- Biohaven Ltd. (NYSE: BHVN), a biopharmaceutical company focused on the discovery, development and commercialization of life-changing treatments...
BHVN June 21st Options Begin Trading
Noteworthy Monday Option Activity: GD, SAM, BHVN
Biohaven Showcases Innovative Neuroscience Portfolio with 20 Presentations at the 2024 American Academy of Neurology (AAN) Annual Meeting and Provides Other Business Updates
Biohaven's first-in-class Molecular Degrader of Extracellular Proteins (MoDE™) technology targeting IgG removal, BHV-1300, was selected for an oral...
Interesting BHVN Put And Call Options For May 17th
Biohaven GAAP EPS of -$1.81 misses by $0.40 (NYSE:BHVN)
Biohaven reports Q4 2023 financial results, with a GAAP EPS of -$1.81, missing expectations by $0.40.
Biohaven Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business Developments
Driving clinical, regulatory, and operational excellence across five innovative platforms focused on immunology, neuroscience, and oncology: Portfolio...
Weight-Loss Drugs Have One Big Problem. These Drugmakers Are Taking It On.
Weight-loss drugs from Novo Nordisk and Eli Lilly lead to massive weight loss. But not all of that weight loss is healthy.
RBC Capital starts Biohaven at outperform, cites epilepsy drug (NYSE:BHVN)
RBC Capital Markets has initiated coverage of Biohaven (BHVN) with an outperform rating, citing the company’s epilepsy drug candidate BHV-7000 and business stra
UBS starts Biohaven at buy, cites diverse pipeline (NYSE:BHVN)
UBS has initiated coverage of Biohaven (BHVN) with a buy rating, citing its attractive valuation and diverse pipeline. The investment bank said it was “bullish
Stocks to Watch: 3 Companies Working on Next-Gen Weight Loss Drugs
The best weight-loss drug stocks firms improving the drugs or developing new, potentially superior weight-loss treatments.
Biohaven Highlights Progress Across Innovative Portfolio and Outlines 2024 Anticipated Milestones at the 42nd Annual J.P. Morgan Healthcare Conference; Established Extensive Portfolio Across 20 Therapeutic Indications in Neuroscience, Immunology and
/PRNewswire/ -- Biohaven Ltd. (NYSE: BHVN) (Biohaven or the Company), a clinical-stage biopharmaceutical company focused on the discovery, development and...
Eli Lilly, Crispr, Biogen Lead Pharma And Biotech Stocks To Great Expectations In 2024
Between buyouts, obesity drugs and neuroscience progress, biotech stocks stand to gain.
Biohaven to Present at the 42nd Annual J.P. Morgan Healthcare Conference
/PRNewswire/ -- Biohaven Ltd. (NYSE: BHVN) today announced that Vlad Coric, M.D., Chairman and Chief Executive Officer, will present at the 42nd Annual J.P....
Commit To Buy Biohaven At $30, Earn 17.3% Annualized Using Options
Biohaven Presents Expanded EEG and Safety Data for BHV-7000 at the American Epilepsy Society Annual Meeting
Biohaven reported full results from the BHV-7000 Phase 1 study examining doses up to 120 mg daily, demonstrating BHV-7000 was well-tolerated at all doses...
Biohaven Non-GAAP EPS of -$1.44 (NYSE:BHVN)
Biohaven reported Q3 2023 financial results with a non-GAAP EPS of -$1.44. Shares declined by 0.34% after hours.
Biohaven Reports Third Quarter 2023 Financial Results and Recent Business Developments
Cash, cash equivalents, marketable securities and restricted cash totaled approximately $495 million on October 5, 2023, which included net proceeds of $242...
Biohaven Presents Preclinical Data Demonstrating Taldefgrobep alfa Reduces Fat and Improves Lean Mass at The Obesity Society's Annual Meeting, ObesityWeek®
- Taldefgrobep is a novel myostatin inhibitor with the potential to be an important therapy for neuromuscular disorders and metabolic diseases including...
Biohaven raises $258.7M from public offering (NYSE:BHVN)
Biohaven raised $258.7M in recent public offering, selling 11.76M shares at $22 per share, which include the full exercise of the underwriters' option.
Friday 10/6 Insider Buying Report: BHVN, AURA
Biohaven Announces Closing of Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares
/PRNewswire/ -- Biohaven Ltd. (NYSE: BHVN), a global clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of...
Biohaven Announces Pricing of $225 Million Public Offering of Common Shares
/PRNewswire/ -- Biohaven Ltd. (NYSE: BHVN), a global clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of...
Biohaven proposes $200M stock offering (NYSE:BHVN)
Biohaven plans to raise $200 million through a public offering of common shares for general corporate purposes. J.P.
BIOHAVEN ANNOUNCES PROPOSED PUBLIC OFFERING OF COMMON SHARES
/PRNewswire/ -- Biohaven Ltd. (NYSE: BHVN), a global clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of...